Trial Profile

A Phase I/Ib Study of BP1002 (a Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BP 1002 (Primary) ; Decitabine (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Sponsors Bio-Path Holdings

Most Recent Events

10 Mar 2025 Planned End Date changed from 1 Sep 2024 to 1 Sep 2027.
10 Mar 2025 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2027.
12 Feb 2025 According to a Bio-Path Holdings media release, the trial has progressed to the fourth, higher dose cohort of 90 mg/m2.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com